Skip to content
Evigrade
MajorImmunosuppressants. Calcineurin inhibitors×Non-steroidal anti-inflammatory drugs (NSAIDs)

Updated · Methodology

Mechanism

A dose-dependent rise in serum creatinine and urea is a common and potentially serious complication of ciclosporin treatment (ciclosporin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The Spanish ciclosporin SmPC lists non-steroidal anti-inflammatory drugs (NSAIDs), including diclofenac, among drugs with synergistic nephrotoxicity (AEMPS). According to the diclofenac SmPC, diclofenac, like other NSAIDs, may increase the nephrotoxicity of ciclosporin through its effect on renal prostaglandins (diclofenac SmPC, AEMPS). With ciclosporin, the bioavailability of diclofenac rises significantly, which may lead to reversible renal impairment. This is most likely due to a reduction of the high first-pass effect of diclofenac. No such rise is expected for NSAIDs with a low first-pass effect, such as acetylsalicylic acid (ciclosporin SmPC, AEMPS). According to the US ciclosporin label, diclofenac blood levels roughly double with this combination, while ciclosporin levels do not change (ciclosporin label, US Food and Drug Administration, FDA).

Symptoms

Ciclosporin commonly raises serum creatinine and urea. With long-term treatment, some people may develop structural kidney changes such as interstitial fibrosis (ciclosporin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Ciclosporin increases the risk of hyperkalaemia, especially in renal impairment, and use with diclofenac may raise potassium levels (ciclosporin and diclofenac SmPCs, AEMPS). Occasional cases of reversible decreases in renal function have been reported with this combination (ciclosporin label, US Food and Drug Administration, FDA). Diclofenac very rarely causes acute renal failure, haematuria, proteinuria, nephrotic syndrome, tubulointerstitial nephritis and renal papillary necrosis. Fluid retention and oedema have been reported with non-steroidal anti-inflammatory drugs, including diclofenac (diclofenac SmPC, AEMPS).

Management

The combination is not contraindicated. With ciclosporin, give diclofenac at lower doses than in people who do not take ciclosporin (diclofenac summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The US ciclosporin label says to keep the diclofenac dose at the lower end of the therapeutic range (ciclosporin label, US Food and Drug Administration, FDA). The ciclosporin SmPC asks for caution with drugs that have synergistic nephrotoxicity, including non-steroidal anti-inflammatory drugs (NSAIDs), and names diclofenac explicitly. Closely monitor renal function throughout concomitant use. If renal function becomes significantly impaired, reduce the dose of the other drug or consider alternative treatment (ciclosporin SmPC, AEMPS). Check blood potassium frequently (diclofenac SmPC, AEMPS). In rheumatoid arthritis, check renal function more often when an NSAID is started or its dose is increased (ciclosporin SmPC, AEMPS). In rheumatoid arthritis and psoriasis, the US ciclosporin label advises checking serum creatinine after starting an NSAID or increasing its dose (ciclosporin label, FDA). The US diclofenac label says to monitor for signs of worsening renal function during use with ciclosporin (diclofenac label, FDA). Diclofenac is contraindicated in severe renal impairment. In people taking drugs that markedly affect renal function, the SmPC recommends monitoring it (diclofenac SmPC, AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Ciclosporin

Other interactions with Diclofenac